FAILED TRIAL: Phase 3 LITESPARK-012 Trial of KEYTRUDA, LENVIMA, and WELIREG did not meet the dual primary endpoints of PFS and OS in 1L RCC April 28, 2026
Darlifarnib + Cabozantinib Demonstrates Robust Activity in Patients With Clear Cell RCC Previously Treated With Cabozantinib April 21, 2026
US FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for MIBC Regardless of Cisplatin Eligibility April 21, 2026
Comprehensive response to FDA OPDP submitted regarding issues related to a television advertisement and a podcast for ANKTIVA April 15, 2026
CT-P71 received Fast Track Designation from US FDA for the treatment of patients with locally advanced or metastatic urothelial carcinoma April 15, 2026
Rinzimetostat RP3D in Combination with Darolutamide selected for Himalayas-1 Ph 3 Global Study with Dose Optimization Data April 7, 2026
QUILT-2.005 randomized clinical trial on track for final analysis and supplemental BLA submission in 2026 for the BCG-naïve NMIBC carcinoma in situ March 31, 2026
FDA Approves Label Update to Accelerate Thaw Time for ADSTILADRIN® (nadofaragene firadenovec-vncg) March 31, 2026
EMA Validates Type II Variation Application for PADCEV + Keytruda in Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer March 24, 2026
TALZENNA Plus XTANDI Significantly Improves Radiographic PFS in Metastatic Prostate Cancer March 24, 2026
NCCN Guidelines Updated to Include ANKTIVA® Plus BCG for Patients With BCG-Unresponsive NMIBC With Papillary-Only Disease March 24, 2026
First-in-human Erda-iDRS (formerly TAR-210) results in intermediate‑risk NMIBC highlighted March 17, 2026
ProstACT Ph 3 Study (Part 1) of TLX591-Tx Achieves Primary Objectives in PSMA+ve metastatic CRPC Patients March 17, 2026
Supplemental BLA for ANKTIVA + BCG in BCG-Unresponsive NMIBC with Papillary Disease Resubmitted to the FDA March 10, 2026
European Commission approves AKEEGA (niraparib & abiraterone dual action tablet) for the treatment of patients with BRCA1/2-mutated metastatic HSPC patients March 10, 2026
Encouraging results for 225Ac-PSMA-Trillium in advanced metastatic prostate cancer reported March 3, 2026
Astellas and Vir Biotechnology to Advance PSMA-targeting PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer March 3, 2026
New real‑world data reinforce earlier use of Pluvicto before chemotherapy in metastatic CRPC March 3, 2026
TARA-002 Demonstrates 68% Complete Response Rate at Six Months in BCG-Unresponsive NMIBC March 3, 2026
Early study results show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer March 3, 2026
ZUSDURI™ Achieves Durable Complete Responses Across EORTC Risk Groups in Patients with Recurrent LG-IR-NMIBC March 3, 2026
